AltRegen is developing ATR211, the first oral, disease-modifying therapy targeting Bruch’s membrane dysfunction in age-related macular degeneration (AMD).

By addressing a fundamental driver of age-related vision loss, ATR211 represents a new therapeutic paradigm beyond symptom management.

ATR211 is currently in a Phase 2b clinical trial in the UK with leading academic centers.

Founded in 2016, AltRegen combines deep expertise in macular degeneration biology with strong translational execution and is actively pursuing global out-licensing, co-development, and M&A opportunities.